Skip to main content

MEI Pharma (MEIP) Stock Plunges 62%

MEI Pharma, Inc. (MEIP) is under heavy pressure this morning, down 63% in pre-market trading after the company said its cancer drug failed to meet the main goal in a mid-stage study. The drug, Pracinostat, in combination with chemotherapy drug azacitidine showed no difference in the rate of complete remission in previously untreated patients with […] View the full post at: MEI Pharma (MEIP) Stock Plunges 62% Related posts: Consumer Credit Plunges $11.1 Billion in March HGSI’s Lupus Drug Shows Great Potential Congress To Hold Hearing on the Circumstances Behind Thursday’s Stock Market Plunge
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.